Több, mint 98% -ának a víruson átesetteknek T sejtes és/vagy virus ellen hatékony antitestes védelemmel rendelkezett. Ez attól függetlenül alakult ki náluk, milyen súlyos volt a betegség lefolyása.
Úgy gondolják, ez hosszú évekre védelmet nyújthat azoknak, akik átestek a víruson.
Én átestem a víruson, és az Orvosok Bibliájának publikációja szerint fogok eljárni a jövőben.
Most már papírotok van róla, megnyugodhattok, nem kell izgulnotok a jövő miatt….
Only two individuals (less than 2%)
had neither antibodies with virus neutralization capacity, nor detectable CD8+ T-cell responses. Hence, we conclude that regardless of COVID19 severity, a robust adaptive immune response towards SARS-CoV-2 is elicited during primary infections.
we conclude that 90% of SARS-CoV-2 infected individuals mount a detectable CD8+ T cell response, towards the nine epitopes tested, irrespectively of disease severity. We further conclude that the broadest targeted epitope in this cohort is located in the spike protein. Lastly, there is an overall weak but statistically significant correlation of antibody responses and CD8+ T-cell responses.Our results show that the majority of patients developed a robust and broad both humoral and cellular immune response to SARS-CoV-2.
We were able to detect SARS-CoV-2 specific antibodies in all but one of the 203 individuals investigated, irrespectively of their disease severity and duration of symptoms.
Nearly all individuals also have SARS-CoV-2 specific IgA responses, clearly indicating functional rigorous class switching and antibody maturation. This presence of IgA is crucial for the immunological protection at mucosal barriers, and hence protection against future SARS-CoV-2 exposures
Here we demonstrate that SARS-CoV-2 spike specific, ACE2 blocking antibodies are found in the majority of infected individuals.
T-cell immunity to SARS-CoV-1 is known to persist for up to six years [47,48], underlining the importance of developing protective cell based immunity to SARS-CoV-2 if long term viral protection is to be obtained.
Only 10% of the investigated individuals did not have a detectable CD8+ T-cell response clearly indicate a strong cytotoxic T-cell component in the immune response towards SARSCoV-2.
https://www.thelancet.com/…/PIIS2352-3964(21)00203-6.pdf
Nielsen SS, Vibholm LK, Monrad I, Olesen R, Frattari GS, Pahus MH, Højen JF, Gunst JD, Erikstrup C, Holleufer A, Hartmann R, Østergaard L, Søgaard OS, Schleimann MH, Tolstrup M. SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity. EBioMedicine. 2021 Jun;68:103410. doi: 10.1016/j.ebiom.2021.103410. Epub 2021 Jun 4. PMID: 34098342; PMCID: PMC8176920.